Normax Extreme Social Impact (ESI) for Stakeholders and Investors2023-05-23T10:46:21+00:00
Download Normax ESI Datasheet
Download Normax ESI Datasheet

The Purpose of Normax is to help save lives

The purpose of Normax is to help save lives with mRNA vaccines, therapies, health technologies and finance, with our people, partners, investors, stakeholders, providers, customers and communities.

Pandemic preparedness

Another pandemic is inevitable- it is just a question of when… Better pandemic preparedness could prevent extreme human and economic costs in the future.


Personalized mRNA Vaccines

mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionized vaccine development and helped to end the COVID-19 pandemic.

mRNA vaccines and therapies by Normax and Vax Factories by Normax can enable better public health and improved healthcare for people, for example, with mRNA vaccines for infectious diseases such as:


The best way to prevent Long COVID is to avoid getting COVID-19. Staying up to date with vaccine boosters against COVID-19 can help protect against severe illness and Long COVID.

22+ Million people died in the COVID-19 pandemic.

65+ Million people are suffering from Long COVID.

COVID cost the global economy $28 Trillion.

TB (Tuberculosis)

TB is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. If not treated properly, TB disease can be fatal.

1.5+ million people die every year from TB.

TV costs the global community about $66 Billion every year.

HIV (Human immunodeficiency virus)

HIV is a virus that attacks the body’s immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome).

1+ million people die every year from HIV/AIDS.

HIV/AIDS costs the global community about $66 Billion every year.

H5N1 Avian Influenza?

The next unknown, but inevitable, breakout pathogen must be controlled before it can become a global pandemic.

WHO reports the Case Fatality Rate of Avian Influenza (2003-23) was 56%.

Pandemic preparedness is vital to public health and economic stability.


The cost of a vaccine

Normax cost to produce mRNA vaccines for infectious disease at large scale is about $2.00 per dose.

Normax plans to price large scale advance purchase agreements for mRNA vaccines for infectious disease at about $4.00 per dose.

$4.00 per vaccine dose at large scale represents a healthy 100% potential profit margin for Normax Investors. However Normax mRNA vaccines can be significantly more cost-effective than other mRNA vaccines which, for example, for COVID are expected to become priced at $100.00 per dose, or more.

We believe in vaccine equity.

Social and economic benefits of Normax

Additional social and economic benefits of Normax include leveraging of Foreign Direct Investment (FDI) with unique financial products for employment (jobs) growth via Domestic and International markets:

  • Pharmaceutical industry jobs
  • Biotech Industry jobs
  • Healthcare services jobs
  • Export Industry jobs
  • Commercial Property Development jobs

mRNA vaccine R&D by Normax enables

  • Competitive projected financial performance on debt & equity for investors

  • Leveraging Foreign Direct Investment (FDI)

  • International Pharmaceutical industry job growth

Vax Factory by Normax enables

  • Affordable domestic mRNA Vaccine Manufacturing Infrastructure

  • mRNA vaccine innovation for infectious disease like COVID, TB, HIV, EBV

  • International export growth; mRNA Vaccines and Vax Factory by Normax

Normax is committed to support GOAL 2050 to end transmission of TB and HIV by 2050.
Learn more about Goal 2050
Normax is committed to a future with NO PANDEMICS.
Learn more about NoPandemics
Go to Top